Dr. Kantor has been a frequent presenter at scientific meetings having served as principle investigator on a variety of biomarker studies including a program to develop innovative blood fingerprinting and optical detection technologies.
Prior to his tenure at SurroMed/PPD, Dr. Kantor served as manager for the rare cell program and cell depletion therapeutic program at AmCell Corp. where he led a team establishing magnetic cell separation applications. He is co-author of more than 40 publications and 12 book chapters in the fields of immunology, cell and molecular biology, biomarkers and clinical medicine. He also received 14 provisional and full patents in the areas of cytometry, informatics and biological markers.
Dr. Kantor received a bachelor's degree in biophysics from the University of Pennsylvania, a doctorate in biophysics from the University of California at Berkeley and was a postdoctoral fellow in cellular and molecular immunology at Stanford University where he developed expertise in flow cytometry applications.
"I am excited to be a part of ITI," said Dr Kantor. "We have a unique opportunity to work at the crossroads of academia and biopharma to advance and industrialize immune system monitoring."
In addition to Drs. Matis and Kantor, ITI's founding management team
also includes Chief Business Officer Stephen Hurst J.D., who came to ITI in
June 2007 and is a veteran of more than 20 years in the biopharmaceutical
industry. Prior to ITI, Mr. Hurst, 52, ran a successful biopharmaceutical
consulting practice, recently advising the G8 governments on global health
policy initiatives, serving as a biopharmaceutical industry expert for the
World Bank and GAVI Alliance (formerly the Global
|SOURCE The Immune Tolerance Institute Inc.|
Copyright©2008 PR Newswire.
All rights reserved